Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment-Reference-Cited by-同舟云学术

Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment

Published:2023-11-15 Issue:2 Volume:65 Page:270-274
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Fouillet Ludovic¹,Daguenet Elisabeth¹^ORCID,Tavernier Emmanuelle¹,Ghesquières Hervé²,Bachy Emmanuel²,Sesques Pierre²,Tournilhac Olivier³,Bay Jacques-Olivier³,Michallet Anne-Sophie⁴,Sapet Manon¹,Chalayer Emilie¹,Guyotat Denis¹,Tinquaut Fabien¹,Cornillon Jérôme¹^ORCID

Affiliation:

1. Institut de Cancérologie et d’Hématologie du CHU de Saint-Etienne (ICHUSE), CHU de Saint-Etienne, Saint-Priest-en-Jarez, France

2. Service d‘Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France

3. Service de thérapie cellulaire et d‘hématologie clinique adulte, CHU de Clermont-Ferrand, Clermont-Ferrand, France

4. Centre Léon Bérard, Lyon, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2281270

Reference13 articles.

1. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

2. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

3. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

4. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

5. Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies